2-[2-(4-(trifluoromethyl)phenylamino)thiazol-4-yl]acetic acid (Activator-3) is a potent activator of AMPK by Bung, Navneet et al.
1SCIenTIfIC RepoRts |  (2018) 8:9599  | DOI:10.1038/s41598-018-27974-1
www.nature.com/scientificreports
2-[2-(4-(trifluoromethyl)
phenylamino)thiazol-4-yl]acetic 
acid (Activator-3) is a potent 
activator of AMPK
Navneet Bung1, Sobhitha Surepalli2, Sriram Seshadri3, Sweta Patel3, Saranya 
Peddasomayajula2, Lalith Kumar Kummari  2,5,6, Sireesh T. Kumar4, Phanithi Prakash Babu4, 
Kishore V. L. Parsa2, Rajamohan Reddy Poondra2, Gopalakrishnan Bulusu1,2 & Parimal Misra2
AMPK is considered as a potential high value target for metabolic disorders. Here, we present the 
molecular modeling, in vitro and in vivo characterization of Activator-3, 2-[2-(4-(trifluoromethyl)
phenylamino)thiazol-4-yl]acetic acid, an AMP mimetic and a potent pan-AMPK activator. Activator-3 
and AMP likely share common activation mode for AMPK activation. Activator-3 enhanced AMPK 
phosphorylation by upstream kinase LKB1 and protected AMPK complex against dephosphorylation 
by PP2C. Molecular modeling analyses followed by in vitro mutant AMPK enzyme assays demonstrate 
that Activator-3 interacts with R70 and R152 of the CBS1 domain on AMPK γ subunit near AMP binding 
site. Activator-3 and C2, a recently described AMPK mimetic, bind differently in the γ subunit of AMPK. 
Activator-3 unlike C2 does not show cooperativity of AMPK activity in the presence of physiological 
concentration of ATP (2 mM). Activator-3 displays good pharmacokinetic profile in rat blood plasma 
with minimal brain penetration property. Oral treatment of High Sucrose Diet (HSD) fed diabetic rats 
with 10 mg/kg dose of Activator-3 once in a day for 30 days significantly enhanced glucose utilization, 
improved lipid profiles and reduced body weight, demonstrating that Activator-3 is a potent AMPK 
activator that can alleviate the negative metabolic impact of high sucrose diet in rat model.
Diabetes is a progressive disease of multiple metabolic disorders. The main cause is the absolute or relative defi-
ciency of insulin. New agents with the properties of increasing insulin sensitivity, lowering glucose and having 
a beneficial effect on lipids, body weight and cardiovascular profiles will have potential health-care benefit. But 
the thiazolidinedione (PPARγ agonist) and glitazar (PPARα/γ dual agonist) saga highlights that the new agent 
should achieve these properties by modulating a different pathway1–5. AMP-activated Protein Kinase (AMPK) is 
a central energy regulator. Condition of energy depletion (low level of ATP) caused due to various stresses like 
prolonged exercise, heat shock, electrical stimulation of muscle or ischemia of muscle and inhibition of oxidative 
phosphorylation leads to the activation of AMPK resulting in replenishment of ATP and cellular energy balance 
by down regulating ATP consuming processes and accelerating ATP generation process6–11. Binding of AMP 
causes allosteric regulation of AMPK leading to change in the conformation and phosphorylation of the Thr172 at 
the kinase domain and protection from the entry and action of phosphatases, thereby preventing deactivation of 
AMPK12,13. In liver, activation of AMPK results in decreased production of plasma glucose, cholesterol, triglycer-
ide and enhanced fatty acid oxidation14,15. In skeletal muscle, activation of AMPK is involved in the stimulation 
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of glucose transport and fatty acid oxidation16–20. In adipose tissue, activated AMPK inhibits deposition of fat, but 
enhances breakdown and burning of stored fat, resulting in reduction of body weight21–23.
It is worth mentioning that AMPK activation by upstream kinase LKB1 mediates glucose homeostasis in 
liver and therapeutic effects of metformin by regulating CREB-PEPCK pathway24. Activated AMPK moderately 
decreases LDL by post translational modification of HMGCoA Reductase, a clinically validated target of stat-
ins25. Activation of AMPK regulates lipid metabolism by controlling the phosphorylation of the two isoforms of 
Acetyl-CoA Carboxylase (ACC). AMPK-mediated phosphorylation of ACC1 inhibits synthesis of free fatty acids 
through the modulation of intracellular concentration of Malonyl-CoA, a clinically validated lipid biomarker. On 
the other hand, phosphorylation of ACC2 accelerates the β-oxidation of the released free fatty acid from triglyc-
erides21,26. Further, adiponectin, a natural AMPK activator, inhibits hypertrophic signaling in the myocardium 
through the activation of AMPK signaling27. Adiponectin may be a treatment of choice for hypertrophic cardi-
omyopathy associated with diabetes and other obesity-related disease27. These clinically well validated pathways 
have less commonality with PPAR-regulated pathways. Thus, AMPK has been identified as a possible diabetes/
obesity target for many years. However, recent advances in structure, function, pathway analysis, HTS assays, 
studies with numerous tool compound activators and the demonstration that activation of AMPK is one of the 
mechanisms of action of the well-established and safe anti-diabetic agent metformin have stimulated a lot of 
interest in AMPK28–37.
AMPK is composed of three different subunits α, β and γ. In mammals, the heterotrimeric complexes com-
bine catalytic α subunit (α1 or α2), with β (β1 or β2) and γ (γ1, γ2 or γ3) regulatory subunits encoded by separate 
genes yielding 12 heterotrimeric combination38–43. The α subunit contains a serine/threonine protein kinase cat-
alytic domain in the N-terminal side, typical of the protein kinase super family44. The catalytic domain has a site 
of phosphorylation at residue Thr172 within the activation loop (T-loop), which is the key target site for AMPK 
activation by upstream kinase44. In the extreme C-terminus side, a region of ~150 amino acid residues is required 
for association with β and γ subunits, whereas the central part seems to possess an inhibitory function45.
AMPK can be directly activated by targeting α, β or γ subunits. The γ subunit has three isoforms (γ1, γ2 or 
γ3) and theoretically, selective modulator of each γ isoform should activate only four isozymes. AMP is a natural 
activator of AMPK and binds to the allosteric site of Cystein-β synthase (CBS) domains of different γ subunits 
(regulatory subunit) and thus indirectly promotes activity at the catalytic domain of α subunit6. The importance 
of AMP binding for AMPK activation is further demonstrated by mutations that localize to the CBS domains of 
the γ subunit in AMPK in Wolff-Parkinson-White Syndrome46–49. 5-aminoimidazole-4-carboxamide riboside 
(AICAR)-derived ZMP is an AMP analog and a potent AMPK activator that binds to the CBS domain of γ sub-
unit6. Intravenous administration of AICAR reduces hepatic glucose output and inhibits whole body lipolysis 
in type 2 diabetic patients demonstrating proof of concept in human30. Though the trial has been conducted in 
very limited patients, AMPK has been validated as a target for diabetes in human. In vivo, AICAR is converted 
to ZMP6. But, AICAR derived ZMP is also a non-specific activator of AMP-binding proteins and long term use 
of this molecule may lead to unwanted side effect50. ZMP is a competitive binder of the natural metabolite AMP 
and binds to same CBS domains in AMPK, may inhibit AMP mediated physiological functions, which could be 
detrimental to the body6,50. There have been multiple allosteric activators of AMPK on the back of the first full 
length X-ray crystal structure published in 201351. These include compound-7, PF-249, PF-739, 991 and MT-8722 
targeted to the allosteric drug and metabolite (ADaM) site of AMPK52–54. The AdaM site is formed at the interface 
of carbohydrate-binding module (CBM) of the β subunit and the N-lobe of the α-kinase domain. The mecha-
nism of action of A-769662, which binds to ADaM site, is one of the most studied aspects of AMPK research, the 
binding site and conformational changes leading to activation is well understood34,51,55–57. Most of the recent drug 
advancements in the AMPK field have been targeted toward the ADaM site, with the exception of Compound-2 
(C2/C13), which is a γ subunit activaton58–60. A novel approach is to develop AMP mimetic small molecules as 
AMPK activators by targeting γ subunit that will have better selectivity and minimal side effects. Here, we report 
in vitro and in vivo characterization of Activator-3, a novel AMP mimetic small molecule and its probable binding 
sites in the CBS domain of the γ subunit of AMPK and its mechanism of action of AMPK activation.
Results
Effects of Activator-3 on AMPK activation in cell based assays. The structure of the natural and 
endogenous activator of AMPK, AMP and ZMP, an analog of AMP are shown in Fig. 1A along with the structures 
of C2, a γ subunit activator and Activator-3, an AMPK activator earlier reported by Dr. Reddy’s Laboratories 
Limited, Hyderabad, India (Fig. 1A)61. Activator-3 could be an AMP mimetic as the pharmacophoric distances 
between the aromatic moiety and the negative charge are similar (Fig. 1A).
A dose dependent response was observed in primary rat hepatocytes and rat myoblast L6 cells treated with 
varying concentrations of Activator-3 for the indicated time points. Activator-3 robustly activated AMPK with an 
EC50 of ~28 nM and ~32 nM for pAMPK in rat primary hepatocytes and L6 rat myoblasts, respectively (Fig. 1B). 
Similar EC50 were observed for pAMPK in HepG2 cells (Fig. S1A) and pACC in HepG2, primary rat hepatocytes 
and L6 cells as well (Supplementary Fig. S1B–D). These data suggest that Activator-3 is a potent nanomolar 
AMPK activator.
Activator-3 directly binds and activates human recombinant AMPK complexes in cell free 
assays. Having observed the effect of Activator-3 on the activation of AMPK in cell based assays, we next 
examined whether Activator-3 could activate AMPK directly or not. For this, we have performed in vitro AMP 
kinase assays with purified human recombinant AMPK isozymes. The dose dependent direct stimulatory effect 
of Activator-3 on in vitro activation of recombinant human AMPK isozymes (α1β1γ1, α2β1γ1, α2β2γ2 and 
α2β2γ3) in the absence of AMP was detected by anti-phospho-ACC (Ser79) ELISA method. The activity of recom-
binant human AMPK (α1β1γ1, α2β1γ1, α2β2γ2 and α2β2γ3) in the presence of vehicle was considered as 100%. 
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Figure 1. Activator-3, an AMPK mimetic is a potent pan-AMPK activator in cell based and cell free assays.  
(A) Chemical structures of Activator-3, AMP, ZMP and C2. Bottom panel: Rationale why Activator-3 may 
likely mimic AMP. (B) pAMPK based dose response curve of Activator-3 in primary rat hepatocytes (left panel) 
and rat L6 myoblasts (Right Panel). Results are expressed as the increase in activity relative to DMSO control 
and represent the mean ± SD for three independent experiments. (C) Human recombinant AMPK complexes 
(α1β1γ1, α2β1γ1, α2β2γ2 and α2β2γ3) expressed in baculo virus were assayed for allosteric activation by 
Activator-3. The representative four AMPK isozymes used for assays represent different combinations of all 
known reported isoforms like α1, α2, β1, β2, γ1, γ2 and γ3. EC50 values were calculated by plotting a non-linear 
curve of log [agonist] vs. response. Results are expressed as the increase in activity relative to DMSO control 
and represent the mean ± SD for three independent experiments. (D) Enzymes allosterically regulated by AMP 
(PFK1) or using AMP as a substrate (AK) were assayed in presence of AMP (≤1 mM) or Activator-3 (≤10 µM). 
Both the enzymes were unaffected by Activator-3. Results are representative of three independent experiments 
conducted using commercially available kits.
www.nature.com/scientificreports/
4SCIenTIfIC RepoRts |  (2018) 8:9599  | DOI:10.1038/s41598-018-27974-1
The EC50 of Activator-3 for the activation of α1β1γ1, α2β1γ1 and α2β2γ2 isozymes were similar. However, the 
activity of Activator-3 against α2β2γ3 was marginally higher (Fig. 1C). This data suggests that Activator-3 is a 
potent pan-AMPK activator in vitro.
Effect of Activator-3 on other AMP- regulated enzymes and protein kinases. AMP is known 
to allosterically modulate several enzymes: 6-phos-phofructo-1 kinase (PFK1), gluconeogenic enzyme 
fructose-1,6-bisphosphatase-1 (FBP1) and phosphorylase b. Further, enzymes such as AMP deaminase-1, 
Adenylate kinase and 5′-nucleotidase use AMP as a substrate62. Thus, to examine the specificity of Activator-3 
for AMPK, we have tested the activity of AMP and Activator-3 against PFK1 and Adenylate kinase using com-
mercially available kits. As expected, AMP activated PFK1 at both the concentrations of 100 µM and 1 mM 
but Activator-3 had no effect on PFK1 even at 10 µM (>330 fold than EC50 of Activator-3 for AMPK; Fig. 1D). 
Moreover, we have tested the effect of Activator-3 on Adenylate kinase which uses AMP as a substrate. Adenylate 
kinase was minimally affected by 1 µM Activator-3 (Fig. 1D).
To determine whether Activator-3 affects the activity of any other protein kinases, we screened it in cell-free 
assays against a panel of 100 protein kinases (Kinexus, Canada). Majority of the protein kinases tested including 
several members of the AMPK-related upstream kinases such as TAK1 and LKB1 were not affected by 10 μM 
Activator-3 except CAMKK2 which exhibited 36% inhibition (Table S1 and S2). Three kinases, DDR1 (−79%), 
SRC (−71%) and ALK5 (−61%) were inhibited by Activator-3 by more than 50% at 10 µM. Further, four other 
kinases, LRRK2 (−34%), PAK1 (−42%), ROR2 (−35%) and PRK1 (−36%) were inhibited by Activator-3 by 
approximately 40% at 10 µM which is >330 fold higher than EC50 for AMPK activation in cell-based assays 
(Table S1). Taken together, these results suggest that Activator-3 is a rather specific AMPK activator.
Activator-3 and AMP share common AMPK activation mode. To understand whether AMP and 
Activator-3 share a common binding and activation mode on the γ subunits, two different sets of experiments 
were performed. 1) AMP competition assay using different AMPK isozymes with Activator-3 concentration 
ranging from 1 nM to 10 μM and maintaining AMP concentration at 100 µM 2) Varied the AMP concentration 
(1 µM to 300 µM) keeping Activator-3 concentration at 30 nM. In the first set of experiments, Activator-3 antago-
nized AMP-dependent AMPK activation, reducing the activity of human recombinant AMPK isozymes α1β1γ1 
and α2β1γ1 stimulated by 100 µM AMP by ~50% (Fig. 2A,B). The isozyme α2β2γ2 showed minimal decrease 
in the activity (Fig. 2C). Surprisingly, co-treatment of α2β2γ3 isozyme with Activator-3 and AMP increased 
AMPK activity >30% than 100 µM AMP alone (Fig. 2D). In the second set of experiments, we have observed 
that increasing concentration of AMP led to progressive enhancement of α1β1γ1 activity compared to the stim-
ulation by 30 nM of Activator-3 alone (Fig. 2E). The above data indicate that AMP and Activator-3 may likely 
share a common binding site on the γ subunit or may function through a similar transduction mechanism as 
hypothesized.
ATP concentration plays an important role in the regulation of AMPK and AMP dependence63. Thus, to 
examine the effect of ATP on Activator-3 mediated AMPK activation, we have studied activation of human 
recombinant α1β1γ1 complex by Activator-3 under two different concentrations of ATP: low (20 µM) and high 
(2 mM; physiological). While 2 mM ATP inhibited AMPK activity at low concentrations of Activator-3, the inhib-
itory effects of ATP were reduced at high concentrations of Activator-3 (Fig. 2F) suggesting that Activator-3 and 
ATP (like AMP/ATP) may compete at the γ subunit allosteric sites and Activator-3 similar to AMP does not 
exhibit co-operative binding at high concentration of ATP63.
Activator-3 enhances AMPK phosphorylation by upstream kinase, LKB1, and protects AMPK 
complex against dephosphorylation by PP2C. AMP allosterically activates AMPK and enhances the 
phosphorylation of pThr172 AMPKα by upstream kinases, a key control point of the overall activation mecha-
nism of AMPK63. As Activator-3 is an AMP mimetic, we speculated that Activator-3 may show similar effect. To 
test this, recombinant AMPK complex was purified from HEK-293T cells overexpressing SFB tagged AMPK γ1 
subunit and activity was studied in the presence of LKB1 alone or in the presence of LKB1 and 100 µM AMP or 
different concentrations of Activator-3 (10–100 nM). This analysis showed that similar to AMP, Activator-3 may 
also modestly enhance the LKB1-mediated phosphorylation of AMPK (Fig. 2G).
It is well documented that AMP activates AMPK allosterically by restricting the access to phosphatase and 
thereby conferring protection from dephosphorylation63. Activator-3, being a mimetic of AMP, was tested 
whether it is able to protect AMPK from dephosphorylation or not. Recombinant human AMPK α2β1γ1 isozyme 
was incubated with protein phosphatase PP2C in the presence or absence of AMP (100 µM) and increasing con-
centrations of Activator-3 (10–100 nM) and observed that similar to AMP, Activator-3 provided protection 
against PP2C mediated dephosphorylation of Thr172 AMPK in a dose dependent manner (Fig. 2H).
Modeling AMPK structure. From in vitro cell based and cell free assays, it was concluded that Activator-3 
is a potent activator of AMPK at nanomolar concentration. It is imperative to understand the binding mode 
of Activator-3. In silico methods such as molecular modeling, docking and dynamics were used to identify the 
binding pocket for Activator-3 molecule. For assembling α1, β1 and γ1 subunits, multiple template homology 
modeling in Modeler was used. The heterotrimeric homology model developed was energy minimized followed 
by multistep MD simulation.
Molecular dynamics simulation of AMPK. The energy-minimized structure was further refined by sub-
jecting it for 20 ns MD simulation (Fig. 3A). The root mean square deviation (RMSD) of the protein backbone 
for each of the subunits with reference to the energy minimized AMPK structure is shown in Supplementary 
Fig. S2A.
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Figure 2. Activator-3 and AMP share common activation mode for AMPK activation and Activator-3 
enhances AMPK phosphorylation by upstream kinase LKB1 and protects AMPK complex from PP2C mediated 
dephosphorylation. (A–D) Recombinant human AMPK α1β1γ1 (A), AMPK α2β1γ1 (B), AMPK α2β2γ2 (C) 
or AMPK α2β2γ3 (D) were assayed in the presence of AMP (100 µM) alone and AMP (100 µM) and increasing 
concentration of Activator-3 (0–10 µM). Results are expressed as percentage increase of AMPK activity relative 
to DMSO control and represent the mean ±SD for three independent experiments. (E) Recombinant human 
AMPK α1β1γ1 was assayed in the presence of Activator-3 (30 nM; ~EC50 concentration in vitro kinase assay) alone 
and Activator-3 (30 nM) and increasing concentrations of AMP (0–300 µM). Results are expressed as percentage 
increase of AMPK activity relative to DMSO control and represent the mean ± SD for three independent 
experiments. (F) Recombinant human AMPK α1β1γ1 was assayed in the presence of low concentration of ATP 
(20 µM) and high and physiological concentration of ATP (2 mM) and increasing concentration of Activator-3 
(0–1 µM). Results are expressed as percentage change of AMPK activity relative to DMSO control (set as 100%). 
Results represent the mean ± SD for three independent experiments. (G) Recombinant AMPK complex was 
purified from HEK-293T cells by transient overexpression of the indicated construct as indicated in methods 
and assayed in presence of LKB1 alone or in presence of LKB1 and 100 µM AMP or increasing concentration of 
Activator-3 (10–100 nM) and the representative blot was quantified. (H) The effects of Activator-3 and AMP on 
dephosphorylation and inactivation of human recombinant AMPK α2β1γ1 by PP2C. Assays were performed 
either using vehicle (pAMPK alone) or with PP2C or vehicle with PP2C + Mg2+ or increasing concentration of 
Activator-3 (10–100 nM) or 100 µM AMP. The blots were probed with indicated antibodies.
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The α subunit showed a minimal change in RMSD (approx. 4 Å) when compared to other subunits 
(Supplementary Fig. S2B). The β subunit showed maximum change in RMSD (approx. 7 Å) due to the long loop 
regions that connect its two segments (Supplementary Fig. S2C). Also, the γ subunit showed high deviation during 
the initial 10 ns of MD simulation due to the movement of N- and C- terminal regions (Supplementary Fig. S2D). 
Residue wise RMSD contribution is shown as a heatmap (Fig. 3B), which revealed maximum deviation for residues 
1–40 (N-terminal of β subunit), 260–269 (C-terminal of β-subunit) and 1–20 (N-terminal of γ subunit).
From the RMSF plot, the maximum fluctuations were observed in most parts of β subunit (Fig. 3B). The fluc-
tuations in the N- and C- termini of various subunits were in accordance with the observations made from the 
heat map calculation (Fig. 3B). Most of the secondary structural elements were stable throughout the simulation 
(Supplementary Fig. S2E).
The structure in the MD trajectory that showed least RMSD to the energy minimized cartesian-averaged 
structure was chosen as the representative structure. The representative structure was evaluated for goodness of 
model by PROCHECK. Based on the distribution of the dihedral angles phi and psi, 889 residues (85.8%) were in 
the most favored region of the Ramachandran map, whereas only 6 residues (0.6%) were in the disallowed region 
(Supplementary Table S3).
Docking of Activator-3 in γ subunit. Finding new sites in the γ subunit. All the co-crystallized small 
organic molecules in the AMPK structure (PDB: 4CFF)51 were removed before docking. Four sites were identified 
for docking using sitemap tool (Schrodinger Software, Germany), out of which three were the existing sites, where 
an AMP molecule is bound in the AMPK crystal structures (PDB: 4CFF, 4CFE). The AMP molecule is bound at 
CBS1, CBS3 and CBS4 domains termed as sites 1, 3 and 4 in the current study. Additionally, a site at the interface 
of the four CBS domains of γ subunit (Site i) was chosen for docking studies.
Docking Activator-3, ZMP and AMP molecules. AMP was used as the reference molecule to validate the dock-
ing protocol (Supplementary Fig. S3). Apart from Activator-3, ZMP was also used for the docking studies. AMP 
binds strongly (with high docking score) at each of the binding sites when compared to ZMP and Activator-3 
molecule (Table 1). AMP docked at site 4 showed highest docking score, reflecting its non-exchangeable nature 
of binding to the CBS4 domain. At site 1, the carboxylate group of Activator-3 interacted with R70 and R152 
residues while the -CF3 group interacted with the backbone of V130 residue (Fig. 4A). The Activator-3 at site 3 
interacted with S242, E274 and R299 residues, while at site 4 it interacts with H151, A205, S214 and D317 residues 
(Fig. S4A,B). Though the center of the grid that was selected for sites 1 and i were different, the docking poses 
Figure 3. Molecular modelling of AMPK. (A) Complete structure of AMPK heterotrimeric complex with 
co-crystallized AMP molecules. The missing residues from the incomplete crystallographic structures were 
homology modeled. α, β and γ subunits are shown in green, blue and gold colors respectively. AMP molecules 
in the complex are shown in blue sticks. Inset shows a closer view of the three AMP bound sites in the γ subunit; 
(B) Heatmap showing residue-wise RMSD contribution of AMPK across the trajectory. The color code in the 
heatmap plot represents the RMSD value for each of the amino acids at a given time-frame. Root mean square 
fluctuations (RMSF) of the Cα atoms in the AMPK heterotrimeric complex are also shown. The vertical line in 
the RMSF plot represents the mean RMSF of the complex.
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of Activator-3 molecule were similar at both the sites (Fig. 4A,D). At site i, apart from the interactions with R70 
and R152, the Activator-3 interacted with K127 and K143 residues. Based on the docking score site 1 (−7.7) and 
site i (−7.4) could be the most probable sites for binding of Activator-3. The high score at sites 1 and i is due to 
the interaction of carboxylate group of Activator-3 with R70 and R152 residues, which act as an anchor for the 
binding of Activator-3.
Comparison of binding of Activator-3 with C2 and AMP molecule. To compare the binding pose of Activator-3 
to the C2 molecule, the X-ray crystal structure of AMPK (PDB Id: 4ZHX)60 was superposed to the representative 
structure of AMPK with docked Activator-3 molecule obtained from MD simulation (Fig. 4C). A careful exami-
nation of the binding pocket showed that the Activator-3 partially overlaps with C2 molecule present at the inter-
face of four CBS domains (Fig. 4C). The carboxylate group of Activator-3 interacted with R70 and R152 residues, 
while the hydroxyl group of C2 molecule interacts with R299 in the γ subunit. The methyl carbon in Activator-3 
molecule provides flexibility to the carboxylate group. It should be noted that in the crystal structure of AMPK 
with C2 bound there were two molecules of C2 per γ subunit60. However, precise stoichiometry of binding of 
Activator-3 could not be established based on docking experiments. The -CF3 group attached to the benzene ring 
of Activator-3 overlapped with the AMP molecule (Fig. 4D). While the other atoms of the Activator-3 overlapped 
with the C2 molecule (Fig. 4C,D).
Docking Activator-3, ZMP and AMP molecules in presence of co-crystallized AMP. Another docking calculation 
was performed, where AMP molecules at sites 1, 3 and 4 were retained. This helped to understand the effect of 
ligand binding cooperativity or the lack of it, during docking calculations. In the presence of AMP at three sites, 
Activator-3 is docked towards the other side of Bateman1 domain (interface of CBS 1 and 2 domains), which 
interacts with the regulatory interacting motif (RIM) 1 and 2 of the α subunit (Fig. 4E). Interestingly, the new 
docking pose of Activator-3 in presence of AMP molecules was also interacting with R70 and R152 residues, 
albeit with a decreased docking score (Fig. 4E). Based on the above experiment we can comment that in the 
absence of AMP molecules Activator-3 binds at site 1, near the CBS1 domain. Activator-3 binds on other side of 
Bateman 1 domain in the presence of AMP at all the three sites (Fig. 4E).
Based on the docking scores of with and without co-docked ligands, R70 and R152 are important for binding 
of Activator-3. These residues are being shared by AMP to allosterically bind AMPK γ subunit. In addition to 
this, a natural mutation R70Q in cardiac muscle cells constitutively activates AMPK and causes cardiomyopathy. 
Therefore, R70 and R152 were chosen and mutated to glycine for in silico and in vitro mutagenesis studies.
Mutational studies. To study the effect of mutations on ligand binding, three simulations were performed: two 
single residue mutations (R70G and R152G) and one double mutant (R70G and R152G; Fig. 5A). It is clear from the 
docking studies that Activator-3 interacts significantly weakly with the mutants compared to the wild type AMPK 
(Fig. S5).The strength of binding for each of the docked complexes was quantified using binding energy. The energy 
of Activator-3 binding to the γ subunit in wild type protein was −288 kJ/mol. Mutations of R70 and R152, respon-
sible for the binding of Activator-3 in the wild-type protein, increased binding energy in all the mutant simulations 
(Fig. 5A) suggesting that residues R70 and R152 are probably crucial for the binding of Activator-3.
Site directed mutagenesis study shows the importance of R70 and R152 residues located in the 
CBS1 domain of AMPK γ1 subunit for binding of Activator-3. In silico analyses showed that R70 and R152 
of CBS1 domain of γ1 subunit are potentially important for the binding of Activator-3 to AMPK. Thus, we mutated 
the respective residues to glycine and overexpressed AMPK γ1 in HEK-293T cells and performed kinase assays with 
Docking Site Molecule Docking score
Site 1
(CBS1)
AMP −12.2
ZMP −8.9
Activator-3 −7.7
Site 3
(CBS3)
AMP −14.1
ZMP −11.8
Activator-3 −5.2
Site 4
(CBS4)
non-exchangeable
AMP −15.1
ZMP −9.6
Activator-3 −4.3
Site I
(At the interface of four CBS domain)
ZMP −7.8
AMP −7.6
Activator-3 −7.4
Docking in presence of AMP at Sites 1, 2 and 3
ZMP −7.1
AMP −5.6
Activator-3 −5.3
Table 1. Docking score of AMP, ZMP and Activator-3 molecules at four sites that were identified in the γ 
subunit after removing all the co-crystallized ligands. Docking calculation was also performed in presence of 
AMP molecule at sites 1, 2 and 3.
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pull down samples (Fig. 5B and Supplementary Fig. S6A,B). The mutant AMPK proteins showed significant reduction 
in AMPK activity upon treatment with Activator-3 or AMP, revealing the importance of these residues in binding of 
Activator-3 to AMPK. However, R70G mutation did not impact the activation of AMPK by AMP (Fig. 5B).
Figure 4. Docking studies of Activator-3 on AMPK. (A–B) AMPK-Activator-3 docked complexes at Site 1 
(A) and Site i (B; Center of four CBS domains); considered for the current study. Activator-3 and interacting 
residues are shown in green and magenta sticks respectively. (C–D) Comparison of binding pose of Activator-3 
with C2 (C) and AMP (D). (E) Activator-3 docked at the center of four CBS domains in presence of AMP 
(pink sticks) at all the three sites known from the crystal structure (PDB ID: 4CFF). In presence of AMP, the 
Activator-3 (green sticks) is docked at other side of R70 and R152 residues (magenta sticks). CBS domains 1, 2, 
3 and 4 are shown in red, blue, cyan and green colors respectively. All the images are shown in stereo view.
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Activator-3 displays good pharmacokinetics profile in rat blood plasma with minimal brain 
penetration property. Male SD rats were orally administered 30 mg/Kg of Activator-3. Blood and brain 
samples were collected at specified time points and were analyzed for Activator-3 using a LC-MS/MS method64–66. 
Systemic exposure of Activator-3 in plasma (AUC) was ~978 µg*h/ml (~3.3 mM) in male SD rats after oral admin-
istration of 30 mg/Kg Activator-3 and t1/2 was 4.11 h post oral dosing (Supplementary Fig. S7). Cmax in plasma 
was determined as ~109 µg/ml (~360 µM). The human plasma protein binding was ~80% (data not shown). No 
significant level of Activator-3 was detected in brain post oral administration (Supplementary Fig. S7). Systemic 
exposure of Activator-3 was very high in plasma compared to brain.
Treatment of HSD fed insulin resistant diabetic rats with Activator-3 improves several metabolic 
parameters. The incremental changes in plasma glucose concentrations of rats following an oral glucose 
intake were observed in the groups. The glucose concentration of the HSD and HSD+Activator-3 group was sig-
nificantly higher than those of control group at 30, 60 and 120 min on day zero (Fig. 6A,B). However on 30th day, 
the glucose concentration of the HSD group treated with Activator-3 was significantly reduced compared to HSD 
rats group (Fig. 6C,D) indicating increased insulin sensitivity in this group of animals (Fig. 6C,D).
At 0 day, plasma total cholesterol, triglyceride and free fatty acid levels were found to be significantly (p < 0.01) 
increased in HSD and HSD+Activator-3 group as compared to control group (Fig. 6E–G). On 30th day, plasma 
total cholesterol and free fatty acid levels of HSD group treated with Activator-3 were significantly lower than 
HSD group alone (Fig. 6E–G). HSD feeding over 30 days slightly increased the body weight of animals as com-
pared to the control diet animal groups (Fig. 6H). Activator-3 treatment of HSD group of animals for 30 days had 
significantly (p < 0.05) decreased HSD induced body weight gain (Fig. 6H). Further, the phosphorylation levels of 
AMPK α subunit and ACC were reduced in the soleus muscle of HSD fed rats and treatment of HSD fed rats with 
Activator-3 has restored the phosphorylation of both AMPK and ACC (Fig. 6I,J, Supplementary Fig. S8). These 
results indicate that the stimulation of the AMPK activation induces hepatic fatty acid oxidation, ketogenesis and 
leads to reduction of cholesterol synthesis, lipogenesis and adipocyte lipolysis in rats fed on a high sucrose diet.
Figure 5. R70 and R152 amino acids γ1 subunit of AMPK are required for Activator-3 mediated AMPK 
activation. (A) The binding energy calculations of Activator-3 bound to wild type and mutant γ subunit of 
AMPK. (B) pACC based in vitro kinase activities of native human recombinant α1β1γ1 AMPK enzyme and 
its mutants using 100 µM AMP and 30 nM Activator-3. The activity shown in the above figure was normalized 
to vehicle control and wild type (WT) control group. Results are the representative of three independent 
experiments. Statistical analysis was performed using Bonferroni’s Multiple Comparison Test *p < 0.05, 
**p < 0.01.
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Discussion
Currently, there is no active pharmacological intervention available to stop or retard the progression of 
pre-diabetes to frank hyperglycemia. AMPK activation could be an important strategy to treat such patients who 
are in transition from pre-diabetic to diabetic stage; however several aspects have to be carefully considered. 1) 
Importantly, proof of concept studies in humans is not available. It is not known to what extent AMPK should be 
activated to achieve desired efficacy. 2) Further, as AMPK activation mimics a part of the physical exercise, it is 
Figure 6. Treatment of HSD rats with Activator-3 improves metabolic health. (A–D) OGTT analysis of control 
and HSD rats on zero day (A and B) and 30 days (C and D). (E–H) Analysis of cholesterol (E), triglyceride (F) 
free fatty acid (G) and body weight (H) of control and HSD fed rats. Statistical analysis were performed using 
one way ANOVA followed by tukey’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. (I,J). Western blot 
analysis of pAMPK, AMPK, pACC, ACC and β-actin of the soleus muscle tissue of normal, HSD fed rats treated 
with vehicle control or 10 mg/kg /day Activator-3 for 30 days.
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not clear whether continuous activation or intermittent activation of AMPK is desirable. 3) Moreover, exercise 
modulates AMP/ATP ratio and thus activates AMPK. Thus, the AMPK activator should show complementary 
activity along with exercise. 4) It is argued that AMPK, a key energy sensor, controls post-translational modifi-
cation and gene transcription. Whilst this makes it as a potent target, it also means that agonists will have signif-
icant effects on multiple pathways that may lead to adverse side effects. 5) Furthermore, inhibition of AMPK in 
hypothalamus reduced food intake while increase in the activity of AMPK in hypothalamus may increase food 
intake67,68. These facts make designing an allosteric activator of AMPK much more challenging.
Activator-3, exerted direct stimulatory effects on the activity of in vitro human recombinant AMPK isozymes 
namely α1β1γ1, α2β1γ1, α2β2γ2 and α2β2γ2 assays and moderate activation (30–40%) of AMPK was sufficient 
to exert in vivo activity in diabetic HSD rats. Furthermore, Activator-3 displayed good pharmacokinetics profile 
in blood plasma: t1/2 ~4 h, good bioavailability and no brain penetration property. Molecular modelling data 
suggested that R70 and R152 of the CBS1 domain of AMPK γ1 subunit are important for Activator-3 binding. 
Enzyme assays with recombinant human AMPK mutants demonstrated that Activator-3 indeed partially requires 
R70 and R152 of the CBS1 domain of γ subunit for its ability to activate AMPK and the same was observed with 
AMP. In case of AMP, R70G mutation has not resulted in a significant reduction in AMPK activation and the pos-
sible reason for this could be other compensating interactions of AMP with CBS domain of AMPK γ1. R70 of γ1, 
R302 of γ2 and R200 of γ3 subunits are similarly conserved amino acids located in their respective CBS domains 
of AMPK47–50,69. γ1 R70Q mutation causes a marked increase in AMPK activity69. Human mutation (R302Q) in 
the γ2 subunit encoded by PRKA γ2 results in chronic AMPK activation and causes cardiomyopathy character-
ized by undesirable effects like hypertrophy and glycogen storage46–49. The finding of increased glycogen content 
in skeletal muscle of Hampshire pigs harboring an R200Q variant in PPKAγ3, which is homologous to R302Q 
PRKAγ2 mutation in man, gives additional support to the role of R302 in the activation of AMPK70. These results 
demonstrate the importance of interaction of Activator-3 with R70 of γ1 for AMPK activation. However, Sanders 
et al. showed that due to R302Q mutation, γ2 subunit had lost its specificity towards both AMP and ATP56. This 
leads the authors to hypothesize that the γ2 subunit adopts a locked conformation as a result of the mutation and 
is no longer amenable for natural deactivation by phosphatases and/or ATP. In view of this, the authors believes 
that, in patients with no mutation in the γ2 subunit of AMPK, chronic activation would not lead to the above 
mentioned cardiac problem. This hypothesis is ably supported by the observations that adiponectin, a natural 
AMPK activator, inhibits hypertrophic signaling in the myocardium through activation of AMPK signaling and 
adiponectin have been use in the treatment of hypertrophic cardiomyopathy associated with diabetes and other 
obesity-related27. α2β2γ2 is the predominantly expressed AMPK isozyme in heart tissue. Activator-3 at saturated 
concentration (1 µM) showed EC50 of ~150% compared to basal activity and even in the presence of 100 µM 
AMP, the activity was minimally changed indicating that Activator-3 is a moderate AMPK activator. However, 
MK-8722 showed Emax of ~250% compared to basal activity indicating higher activation of α2β2γ2 isozyme54. 
Activation of AMPK should mimic the benefits of the bout of the exercise. The half-life of Activator-3 is ~4.0 h. 
Because of the short half-life and moderate Emax of activation, we speculate that Activator-3 may not be able to 
cause negative impact on the heart. Exogenous activators tend to bind in a site different to that of an endogenous 
activator (like AMP in AMPK) and stabilize the active conformation52–54. The purpose of utilizing computational 
tools is to find additional allosteric sites either in CBS domain or in the N-terminal of γ1 subunit of AMPK, 
because the mode of activation of Activator-3 is not completely understood. Molecular modelling study demon-
strated that Activator-3 and AMP bind to and interact with few common and different amino acids located in 
the CBS domain of the AMPK γ subunit. The nature of the activator-binding pocket of Activator-3 suggests the 
involvement of additional sites of CBS domain of γ subunit of likely physiological importance in the regulation 
of AMPK. Importantly, these results offer new opportunities for the design of small molecule direct activators of 
AMPK which should act synergistically with AMP for treatment of metabolic disorders.
Materials and Methods
Homology modeling. The structure of complete α1β1γ1 isoform of human AMPK is not known 
(Supplementary Table S4). The available crystal structures (PDB ID: 4CFF and 4CFE) of human AMPK are 
incomplete and all the subunits of the heterotrimeric protein have missing residues (Supplementary Fig. S9)51. 
Therefore, the structures of all the three subunits were modeled independently and assembled based on the 
human α2β1γ1 isoform structure (4CFF).
α1 subunit. The complete primary sequence of human α1 subunit (Uniprot ID: Q13131) was retrieved from 
Uniprot protein knowledge base71. Sequence alignment with crystallized rat α1 subunit (4CFH_A) has shown 
three large gap regions corresponding to N-terminal (1–20), Auto-Inhibitory domain (AID) (292–331) and 
C-terminal (482–538). The structure of AID was modeled using 4F2L (PDB ID) as the template72. No signifi-
cant templates could be identified for N- and C-terminal gap regions. So, complete sequence was submitted to 
I-TASSER73 for ab inito modeling.
β1 subunit. The primary sequence of human β1 subunit (Uniprot ID: Q9Y478) was retrieved from Uniprot 
protein knowledge base. The full length AMPK structures, 4CFE and 4CFF, have allosteric activating drugs 991 
and A-769662 bound in the ADaM site51. The coordinates of CBM are reported in the 4CFF and 4CFE crystal 
structures. The coordinates were also reported for the 42 amino acid long loop region that joins two parts of β 
subunit. A homology model was generated using I-TASSER server, with 4CFF_B chain as user defined template.
γ1 subunit. The coordinates of γ1 subunit were available in PDB (PDB ID: 4CFF). The N-terminal missing res-
idues (1–26) in the γ subunit were modeled using I-TASSER server.
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Heterotrimerization of AMPK. To generate the heterotrimeric complex of AMPK, the homology models 
of α1, β1 and γ1 subunits were superposed on the 4CFF AMPK structure. In AMPK heterotrimeric form, α and 
γ subunits interact head to head and a part of β subunit is placed in the cavity formed at the interface of α and γ 
subunits. After superposition of α1 and γ1 subunit on to 4CFF_A and 4CFF_E chains respectively the superposi-
tion of β1 subunit resulted in clashes with the α subunit. Modeller74 was used to re-model the β1 subunit into the 
heterotrimeric form by using the I-TASSER modeled β1 subunit as the template. To further refine the structure, 
energy minimization and molecular dynamic simulations were performed after docking the co-crystallized acti-
vators and inhibitors.
Molecular dynamics. To check the stability of the homology modeled AMPK heterotrimeric structure 
explicit solvent molecular dynamics simulation was performed using Gromacs 4.5.559 with amber99sb-ildn force 
field75. Force field parameters for the activator and inhibitor were obtained using antechamber tool76. The system 
was solvated in an octahedron box with a 9 Å layer of TIP3P model water molecules; protein charges were neu-
tralized by adding sodium ions. The system was then energy minimized using steepest descent followed by NVT 
and NPT position restrained equilibration for 200 ps and 500 ps respectively77. A weight of 1000 kcal/mol Å2 was 
used to restrain the heavy atoms during the equilibration step. The temperature was gradually raised from 0 K 
to 300 K at 3 K/ps. Bond lengths were constrained using LINCS algorithm. Periodic boundary conditions were 
employed to minimize edge effects and the electrostatic computations were done using Particle Mesh Ewald78 
with interpolation order of 4, tolerance of 1e-5 and Fourier spacing of 1.6 Å. Production run of 20 ns was per-
formed on the ligands docked-AMPK complex using NPT ensemble. The goodness of the modelled structure was 
evaluated using PROCHECK79.
Docking of Activator-3 in the γ subunit. AMP, ZMP and Activator-3 were minimized using the ligprep 
module of Schrodinger. Ligands were docked using extra precision (XP) mode80. Post docking, minimization was 
performed on each of the docked complexes and a strain correction term was added to the final score. 10 poses 
were generated for each of the docking calculations. The structure with best docking score was selected for further 
analyses. To check for persistent interactions during the docking studies, the enzyme-activator complexes were 
minimized and subjected to molecular dynamic simulations using the protocol mentioned above. Production 
run of 10 ns was performed on the Activator-3 docked AMPK complex using NPT ensemble. Binding energies 
for the trajectories obtained from MD simulations for each of the complexes were calculated using g_mmpbsa81 
module of Gromacs82.
Cell culture materials and reagents. Cell lines HepG2 (ATCC Cat. No. HB-8065) and L6 myoblasts 
(ATCC Cat. No. CRL-1458) were cultured in DMEM containing 10% FBS (Fetal Bovine Serum) at 37 °C and 5% 
CO2. When the cells reached confluence, cells were trypsinzed with 0.05% Trypsin for 5 min. Activity of trypsin 
was inhibited by addition of equal volume of 10% FBS + DMEM and cells were centrifuged at 200 g for 3 min. 
Pellet was re-suspended in 1 ml of complete medium and cells were counted using hemocytometer.
Primary hepatocytes isolation. Primary rat hepatocytes were isolated by collagenase (type4, Invitrogen: 
Cat# 17104-019) digestion as described previously83. Digested cells were suspended in DMEM supplemented 
with 10% FBS. Cells were seeded into 96-well plate (20,000 cells per well) pre-coated with collagen (2 mg/ml). As 
the cells were metabolically active, medium was changed after cells have attached and allowed to incubate over-
night before performing cell based assay.
Cell based ELISA. Approximately 40,000 cells per well were seeded into a 96 well plate (Biofil, cat# 
TCP011096) and incubated overnight at 37 °C and 5% CO2. After the seeded cells reached 80% confluence, cells 
were treated with Activator-3 with different working concentrations and 500 μM AICAR (Caymen chemicals, 
cat# 10010241-10) and incubated for 30 min to 2 h (depending upon the primary antibody used) at 37 °C and 5% 
CO2. Medium was aspirated and fixed with 4% of formaldehyde solution (diluted in 1X PBS) incubated for 1 h at 
4 °C on shaker. Cells were washed with tween 20 (diluted in 1X PBS) on shaker for 5 minutes at room temperature 
(3 times). To quench the endogenous peroxidase activity cells were incubated with 100 µl per well of quenching 
solution (1% H2O2 in 1X PBS) in dark. Plate was incubated for 45 minutes at 37 °C and 5% CO2. Subsequently 
plate was washed three times as mentioned above. A permeabilization step was done by adding 100 µl per well of 
0.05% Triton–X–100 and incubated for 5 min on shaker at room temperature and washed 3 times appropriately. 
To avoid nonspecific binding of antibody, cells were blocked by adding 300 µl per well of 5% BSA and incubated 
for 1 h on shaker at room temperature followed by overnight incubation with pAMPK (Thr172)/pACC (Ser79) 
diluted in 5% BSA (1:1000 dilution; Cat#2531/3661 Cell Signaling technology). To quantify the bound primary 
antibody, cells were probed with a HRP conjugated secondary anti-rabbit antibody (1:2000 dilution, Bio-Rad; 
Cat# 170-6515) diluted in 1X PBST and incubated 2 h at RT on rocker. After 2 h incubation, plate was washed 
firmly with the washing solution for 3 times and subsequently added 1X TMB/H2O2, (Bangalore Genei: 106035) 
in dark and incubated till the color is developed. This reaction is stopped by adding 2 N H2SO4 and plate was 
immediately read at 450 nm using UV–Vis Spectrophotometer.
In vitro AMP kinase assay. In vitro kinase assay was done with recombinant human AMPK α1β1γ1, 
α2β1γ1, α2β2γ2 and α2β2γ3 isozymes (50 ng per well: SignalChem, Cat# P47-10H-05/P48-10H-05) either with 
Activator-3 or AMP or AMP and Activator-3 as described in different experiments. A high binding Enzyme 
Immuno Assay (EIA) 96-well plate (Sigma: Cat# CLS3590) was coated with Acetyl CoA Carboxylase 2 (ACC: 
175–271 amino acids) peptide, a direct substrate for AMPK, 100 ng per well (1:1000 ratio, Cat# 12–491, Upstate 
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biotechnology) and incubated overnight at 25 °C. Reaction mixture was incubated at 30 °C for 2 h and reaction 
was stopped by washing the plate with 0.05% Tween 20 followed by incubation with pACC primary antibody and 
rabbit secondary antibody as described in cell based ELISA section. Assay buffer is composed of 10 mM DTT, 
100 mM magnesium acetate, 50 μM ATP and 10 mM HEPES.
Phosphatase protection Assay. Human recombinant α2β1γ1 isozyme was incubated with Activator-3 
or AMP for 30 min at 30 °C in 10 mM MgCl2, 10 mM DTT, 50 mM Tris-HCl pH 7.4 and 0.5% Triton-X-100 and 
was then incubated with human recombinant PP2C (Catalog # 12984-H08E: Sino Biologicals) for about 30 min. 
The reaction was stopped by adding SDS-loading dye immediately to the reaction mixtures followed by boiling 
the samples at 95 °C for 10′. These samples were run on a 10% SDS-PAGE and probed for AMPK and pAMPK 
(1:1000; Cell Signaling Technologies).
Phosphorylation by Activator-3 mediated by LKB1. SFB (S-protein, Flag and Streptavidin binding 
peptide) tagged AMPK γ1 sub-unit was overexpressed in HEK-293T cells and precipitated with streptavidin 
beads. The precipitates were incubated with either Activator-3 or AMP in 10 mM Magnesium Acetate, 10 mM 
DTT, 50 mM Tris-HCl pH-7.4 and 50 µM ATP for 30 min at 30 °C and subsequently human recombinant LKB1 
(Catalog # AB119736: Abcam) was added and incubated under same conditions. This reaction was immediately 
stopped with SDS-loading dye and resolved on 10% SDS-PAGE and probed for AMPK and pAMPK (1:1000; Cell 
Signaling Technologies).
PFK and AK activity assays using Activator-3. Effect of Activator-3 on AMP regulated enzymes such as 
Phospho Fructo Kinase1 (PFK1) (Catalog # K776-100: Biovision) and Adenylate Kinase (AK) (Catalog # K350–
100: Biovision) was studied using the activity assay kits following manufacturer’s instructions.
Site directed mutagenesis, transfection and pull down. R70 and R152 residues in AMPK γ1 subunit 
(pDONR223-PRKAG1: purchased from addgene, cat# plasmid#23718) are mutated to glycine using overlapping 
extension PCR. Subsequently, the mutants were transferred into a triple tagged destination vector (Streptavidin, 
Flag and Biotin; SFB-pDEST) by using gateway cloning technology. The mutant DNA was transfected into HEK-
293T cells using PEI following standard procedures. After 4 h of transfection, media was changed to DMEM 
containing 10% FBS. Cells were lysed in TENNS lysis buffer (20 mM Tris pH:8.0, 100 mM NaCl, 1 mM EDTA, 
10 mM Na2H2P2O7, 10 mM NaF, 10 mM Na3VO4, 0.5% NP40) and subjected to pull down using streptavidin 
beads followed by biotin elution. To protect the protein from dephosphorylation, cells were treated with 500 μM 
AICAR prior to lysis. This purified protein was estimated by using nanodrop and taken for in vitro kinase assay 
to check whether Activator-3 is binding to the mutant AMPK or not, and the activity of the mutant protein was 
assessed by comparing with the wild type protein activity.
Western blotting. Approximately 100 mg of soleus muscle tissue was taken and lysed with RIPA lysis buffer. 
Lysates were resolved on 12% SDS–polyacrylamide gels and were transferred to PVDF membrane (Millipore, 
USA). Membrane was blocked with 5% nonfat milk in TRIS buffered saline (TBS; 10 mM TRIS (pH 8.0), 150 mM 
NaCl) for 1 hour and probed with primary antibody of interest: phospho-AMPK (Thr172) (1:1000; Cell Signaling 
Technology, USA), phospho-ACC (Ser79) (1:1000; Cell Signaling Technology, USA), total AMPK (1:1000; Cell 
Signaling Technology, USA), total ACC (1:1000; Cell Signaling Technology, USA), and total Actin (1:1000; Santa 
Cruz Biotechnology, USA). Subsequently, membranes were incubated with corresponding HRP-conjugated 
secondary antibodies. The chemiluminescence signals were captured on photographic films using an enhanced 
chemiluminescence (Thermo Scientific, USA).The loading controls of phospho-ACC and phospho-AMPK in 
Fig. 6J were probed in parallel gels.
Statistical Analysis. Values were expressed as mean ± SD. For comparison between 2 groups, the unpaired 
Student’s t test was used. For comparisons of 2 or more groups Two-Way ANOVA was used followed by 
Bonferroni’s post-hoc analysis, p < 0.05 was considered as significant.
Pharmacokinetic study in male rats. Male SD rats were orally administered with 30 mg/Kg of 
Activator-3. Blood and brain samples were collected at specified time points and were analyzed for Activator-3 
using optimized LC-MS/MS method64–66.
Animal treatment. Twelve weeks old healthy colony bred male Wistar rats, weighing about 150–200 grams 
were purchased from the animal research facility (Cadila Pharma limited, Ahmedabad, India) and maintained 
at the animal house of Institute of pharmacy (Nirma University, India). All the methods were carried out in 
accordance with the approved guidelines. Experimental protocol involving animals was reviewed and approved 
by the Animal Ethical Committee of Institute of Science, Nirma University, Ahmedabad, India (Protocol No. IS/
FAC/14-1/021) Animals were maintained in polypropylene cages in a standard photoperiod (12 h light:12 h dark 
cycle) and temperature (27 ± 1 °C) controlled room with the provision of laboratory food (Gold Mohur feeds Ltd, 
New Delhi, India) and water ad libitum. Animals were segregated into three different experimental groups with 6 
animals in each as follows: non-diabetic group with standard chow diet (control group, CD), Diabetic group with 
high sucrose diet (65%, treated group, HSD)84 and HSD with AMPK Activator-3 treated group (10 mg/kg body 
weight of animal). Post HSD induction animals were treated with AMPK Activator-3 for 30 days.
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Oral Glucose Tolerance Test (OGTT). Animals were subjected to an OGTT at a beginning of the treat-
ment (0 day) and a day before the end of the experiment (30 day). OGTT was performed after 12 h of the fasting. 
Briefly, after fasting, animals were given a glucose load (2 g/kg) orally. Blood samples were collected from the 
animal tail vein at 0 min (before glucose administration) and at 15, 30, 60, 90 and 120 min after glucose admin-
istration. Glucose concentration was determined using a CareSensN blood glucose monitor and glucose strips. 
Area under the curve for glucose (AUCglucose) was calculated using the trapezoidal rule.
Blood collection. Approximately, 1 ml of the blood samples was collected from the retro-orbital plexus of 
the animals under the mild anesthesia using diethyl ether. Blood was then transferred to the microfuge tubes for 
separation of plasma and serum at 0 day (start of the treatment) and the last day of the experiment (30 day). Total 
cholesterol and triglycerides levels were estimated from plasma using a diagnostic kit from Accucare India Ltd 
according to the protocol mentioned by the manufacturer.
FFAs and Insulin Estimation. Plasma FFA was estimated using chloroform and triethyalanomine extrac-
tion method by measuring the absorbance at 440 nm. The stearic acid was used as standard fatty acid and detailed 
protocol was performed as mentioned85,86. Fasting Insulin level from the serum samples were estimated using 
radioimmunoassay methods.
References
 1. Psaty, B. M. & Furberg, C. D. The record on rosiglitazone and the risk of myocardial infarction. N. Engl. J. Med. 357, 67–69 (2007).
 2. Nissen, S. E., Wolski, K. & Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 
2 diabetes mellitus. JAMA 294, 2581–2586 (2005).
 3. Henry, R. R. et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of 
cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet Lond. 
Engl. 374, 126–135 (2009).
 4. Lincoff, A. M. et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes 
mellitus: the AleCardio randomized clinical trial. JAMA 311, 1515–1525 (2014).
 5. Cavender, M. A. & Lincoff, A. M. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular 
disease in patients with diabetes mellitus. Am. J. Cardiovasc. Drugs Drugs Devices Interv. 10, 209–216 (2010).
 6. Hardie, D. G. & Carling, D. The AMP-activated protein kinase–fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259–273 
(1997).
 7. Winder, W. W. & Hardie, D. G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle 
during exercise. Am. J. Physiol. 270, E299–304 (1996).
 8. Hutber, C. A., Hardie, D. G. & Winder, W. W. Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-
activated protein kinase. Am. J. Physiol. 272, E262–266 (1997).
 9. Kudo, N., Barr, A. J., Barr, R. L., Desai, S. & Lopaschuk, G. D. High rates of fatty acid oxidation during reperfusion of ischemic hearts 
are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA 
carboxylase. J. Biol. Chem. 270, 17513–17520 (1995).
 10. Corton, J. M., Gillespie, J. G. & Hardie, D. G. Role of the AMP-activated protein kinase in the cellular stress response. Curr. Biol. CB 
4, 315–324 (1994).
 11. Witters, L. A., Nordlund, A. C. & Marshall, L. Regulation of intracellular acetyl-CoA carboxylase by ATP depletors mimics the 
action of the 5′-AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 181, 1486–1492 (1991).
 12. Hardie, D. G. The AMP-activated protein kinase pathway–new players upstream and downstream. J. Cell Sci. 117, 5479–5487 (2004).
 13. Kemp, B. E. et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24, 22–25 (1999).
 14. Foretz, M. et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild 
hypoglycemia and fatty liver. Diabetes 54, 1331–1339 (2005).
 15. Viollet, B. et al. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci. Landmark Ed. 14, 3380–3400 
(2009).
 16. Fisher, J. S., Gao, J., Han, D.-H., Holloszy, J. O. & Nolte, L. A. Activation of AMP kinase enhances sensitivity of muscle glucose 
transport to insulin. Am. J. Physiol. Endocrinol. Metab. 282, E18–23 (2002).
 17. Iglesias, M. A. et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant 
high-fat-fed rats. Diabetes 51, 2886–2894 (2002).
 18. Vavvas, D. et al. Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. J. Biol. 
Chem. 272, 13255–13261 (1997).
 19. Chen, Z. P. et al. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. 
Am. J. Physiol. Endocrinol. Metab. 279, E1202–1206 (2000).
 20. Dean, D. et al. Exercise diminishes the activity of acetyl-CoA carboxylase in human muscle. Diabetes 49, 1295–1300 (2000).
 21. Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. & Wakil, S. J. Continuous fatty acid oxidation and reduced fat storage in mice 
lacking acetyl-CoA carboxylase 2. Science 291, 2613–2616 (2001).
 22. Daval, M. et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280, 25250–25257 (2005).
 23. Sponarova, J. et al. Involvement of AMP-activated protein kinase in fat depot-specific metabolic changes during starvation. FEBS 
Lett. 579, 6105–6110 (2005).
 24. Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642–1646 
(2005).
 25. Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425–430 (1990).
 26. Ruderman, N. B., Saha, A. K., Vavvas, D. & Witters, L. A. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276, 
E1–E18 (1999).
 27. Shibata, R. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384–1389 (2004).
 28. Pang, T. et al. Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits. J. Biol. Chem. 
282, 495–506 (2007).
 29. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes 
and the metabolic syndrome. Cell Metab. 3, 403–416 (2006).
 30. Boon, H. et al. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 
diabetic patients. Diabetologia 51, 1893–1900 (2008).
 31. Cantó, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056–1060 
(2009).
www.nature.com/scientificreports/
1 5SCIenTIfIC RepoRts |  (2018) 8:9599  | DOI:10.1038/s41598-018-27974-1
 32. Viswakarma, N. et al. The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP 
kinase. J. Biol. Chem. 288, 27898–27911 (2013).
 33. Misra, P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin. Ther. Targets 12, 91–100 
(2008).
 34. Calabrese, M. F. et al. Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite 
poles by different molecular mechanisms. Struct. Lond. Engl. 1993 22, 1161–1172 (2014).
 35. Xiao, B. et al. Structure of mammalian AMPK and its regulation by ADP. Nature 472, 230–233 (2011).
 36. Carling, D., Mayer, F. V., Sanders, M. J. & Gamblin, S. J. AMP-activated protein kinase: nature’s energy sensor. Nat. Chem. Biol. 7, 
512–518 (2011).
 37. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).
 38. Carling, D. et al. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the 
regulation of carbon metabolism. J. Biol. Chem. 269, 11442–11448 (1994).
 39. Davies, S. P. et al. Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. 
Eur. J. Biochem. 223, 351–357 (1994).
 40. Mitchelhill, K. I. et al. Mammalian AMP-activated protein kinase shares structural and functional homology with the catalytic 
domain of yeast Snf1 protein kinase. J. Biol. Chem. 269, 2361–2364 (1994).
 41. Stapleton, D. et al. Mammalian 5′-AMP-activated protein kinase non-catalytic subunits are homologs of proteins that interact with 
yeast Snf1 protein kinase. J. Biol. Chem. 269, 29343–29346 (1994).
 42. Stapleton, D. et al. Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611–614 (1996).
 43. Woods, A. et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric 
complex in vitro. J. Biol. Chem. 271, 10282–10290 (1996).
 44. Hanks, S. K., Quinn, A. M. & Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic 
domains. Science 241, 42–52 (1988).
 45. Stein, S. C., Woods, A., Jones, N. A., Davison, M. D. & Carling, D. The regulation of AMP-activated protein kinase by 
phosphorylation. Biochem. J. 345(Pt 3), 437–443 (2000).
 46. Gollob, M. H. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 344, 
1823–1831 (2001).
 47. Gollob, M. H. et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction 
system disease with childhood onset and absence of cardiac hypertrophy. Circulation 104, 3030–3033 (2001).
 48. Yu, H. et al. Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase gamma3-subunit 
differentially regulates glycogen accumulation. Am. J. Physiol. Endocrinol. Metab. 291, E557–565 (2006).
 49. Arad, M. et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. 
J. Clin. Invest. 109, 357–362 (2002).
 50. Hürlimann, H. C. et al. Physiological and toxic effects of purine intermediate 5-amino-4-imidazolecarboxamide ribonucleotide 
(AICAR) in yeast. J. Biol. Chem. 286, 30994–31002 (2011).
 51. Xiao, B. et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 4, 3017 (2013).
 52. Cameron, K. O. et al. Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-
carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the 
Potential Treatment of Diabetic Nephropathy. J. Med. Chem. 59, 8068–8081 (2016).
 53. Cokorinos, E. C. et al. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human 
Primates and Mice. Cell Metab. 25, 1147–1159.e10 (2017).
 54. Myers, R. W. et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 
357, 507–511 (2017).
 55. Göransson, O. et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 
282, 32549–32560 (2007).
 56. Sanders, M. J. et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a 
member of the thienopyridone family. J. Biol. Chem. 282, 32539–32548 (2007).
 57. Langendorf, C. G. & Kemp, B. E. Choreography of AMPK activation. Cell Res. 25, 5–6 (2015).
 58. Gómez-Galeno, J. E. et al. A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis. ACS Med. Chem. Lett. 1, 
478–482 (2010).
 59. Hunter, R. W. et al. Mechanism of action of compound-13: an α1-selective small molecule activator of AMPK. Chem. Biol. 21, 
866–879 (2014).
 60. Langendorf, C. G. et al. Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 
binding. Nat. Commun. 7, 10912 (2016).
 61. Misra, P. et al. Modulation of endogenous AMPK levels for the treatment of obesity. WO/2009/019600 A2 (12 February, 2009).
 62. Vincent, M. F., Marangos, P. J. & Gruber, H. E. & Van den Berghe, G. Inhibition by AICA riboside of gluconeogenesis in isolated rat 
hepatocytes. Diabetes 40, 1259–1266 (1991).
 63. Gowans, G. J., Hawley, S. A., Ross, F. A. & Hardie, D. G. AMP is a true physiological regulator of AMP-activated protein kinase by 
both allosteric activation and enhancing net phosphorylation. Cell Metab. 18, 556–566 (2013).
 64. Hartmann, C., Smeyers-Verbeke, J., Massart, D. L. & McDowall, R. D. Validation of bioanalytical chromatographic methods. J. 
Pharm. Biomed. Anal. 17, 193–218 (1998).
 65. Fan, J. & de Lannoy, I. A. M. Pharmacokinetics. Biochem. Pharmacol. 87, 93–120 (2014).
 66. Banker, M. J., Clark, T. H. & Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring 
plasma protein binding. J. Pharm. Sci. 92, 967–974 (2003).
 67. Minokoshi, Y. et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 
428, 569–574 (2004).
 68. Andersson, U. et al. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279, 12005–12008 (2004).
 69. Hamilton, S. R. et al. An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. FEBS Lett. 500, 163–168 
(2001).
 70. Milan, D. et al. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288, 1248–1251 
(2000).
 71. UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 43, D204–212 (2015).
 72. Chen, L. et al. Conserved regulatory elements in AMPK. Nature 498, E8–10 (2013).
 73. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. 
Protoc. 5, 725–738 (2010).
 74. Fiser, A. & Sali, A. Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol. 374, 
461–91 (2003).
 75. Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 1950–1958 
(2010).
 76. Sousa da Silva, A. W. & Vranken, W. F. ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res. Notes 5, 367 (2012).
 77. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007).
www.nature.com/scientificreports/
1 6SCIenTIfIC RepoRts |  (2018) 8:9599  | DOI:10.1038/s41598-018-27974-1
 78. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 
10089–10092 (1993).
 79. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of 
protein structures. J. Appl. Crystallogr. 26, 283–291 (1993).
 80. Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand 
complexes. J. Med. Chem. 49, 6177–6196 (2006).
 81. Kumari, R. & Kumar, R. Open Source Drug Discovery Consortium & Lynn, A. g_mmpbsa–a GROMACS tool for high-throughput 
MM-PBSA calculations. J. Chem. Inf. Model. 54, 1951–1962 (2014).
 82. Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable 
Molecular Simulation. J. Chem. Theory Comput. 4, 435–447 (2008).
 83. Kapadia, B. et al. ERK2-mediated phosphorylation of transcriptional coactivator binding protein PIMT/NCoA6IP at Ser298 
augments hepatic gluconeogenesis. PloS One 8, e83787 (2013).
 84. Prajapati, B., Rajput, P., Jena, P. K. & Seshadri, S. Investigation of Chitosan for Prevention of Diabetic Progression Through Gut 
Microbiota Alteration in Sugar Rich Diet Induced Diabetic Rats. Curr. Pharm. Biotechnol. 17, 173–184 (2015).
 85. Yadav, H., Jain, S. & Sinha, P. R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in 
high fructose fed rats. Nutr. Burbank Los Angel. Cty. Calif 23, 62–68 (2007).
 86. Kain, V. et al. Co-activator binding protein PIMT mediates TNF-α induced insulin resistance in skeletal muscle via the 
transcriptional down-regulation of MEF2A and GLUT4. Sci. Rep. 5, 15197 (2015).
Acknowledgements
Authors thank Dr. Reddy’s Laboratories, Hyderabad for the generous gift of Activator-3. P.M. and R.R.P. thank 
the financial support from DBT, India (BT/PR15214/BRB/10/903/2011). The authors thank Ms. S. Behera, Dr. B. 
Kapadia and Ms. B. Prajapathi for technical assistance. The authors thank Dr. M. Subbareddy (CDFD, India) for 
the kind gift of SFB triple tagged gateway destination construct. P.M. and R.R.P. thank Dr. A. Venkateswarlu, Dr. 
Uday Saxena and Dr. Javed Iqbal for helpful discussion and suggestions at various stages of this project.
Author Contributions
N.B., S. Surepalli, S. Peddasomayajula, L.K.K. have done molecular modeling analysis. S. Surepalli and S. Patel 
have done HSD rat experiments. S. Surepalli has done in vitro experiments and western blot analysis. S.T.K. and 
P.P.B. have contributed to the primary hepatocyte experiments. G.B. and P.M. have conceptualized the study. G.B., 
P.M. and K.V.L.P. have designed the experiments. G.B., P.M., R.R.P. and K.V.L.P. interpreted the data and written 
the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-27974-1.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
